cyproterone acetate has been researched along with cv 1808 in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (50.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Abiru, T; Homma, H; Matsuda, A; Murayama, T; Nomura, Y; Watanabe, Y | 1 |
de Jesus, R; Ghai, GR; Hutchison, AJ; Jarvis, MF; Oei, HH; Stone, GA; Webb, RL; Williams, M; Yokoyama, R; Zoganas, HC | 1 |
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
4 other study(ies) available for cyproterone acetate and cv 1808
Article | Year |
---|---|
Nucleosides and nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: a new entry of selective A2 adenosine receptor agonists with potent antihypertensive activity.
Topics: Adenosine; Animals; Antihypertensive Agents; Brain; Male; Molecular Structure; Rats; Rats, Inbred SHR; Receptors, Purinergic; Substrate Specificity | 1992 |
2-(Arylalkylamino)adenosin-5'-uronamides: a new class of highly selective adenosine A2 receptor ligands.
Topics: Adenosine; Animals; Brain; Coronary Circulation; Heart Rate; In Vitro Techniques; Indicators and Reagents; Ligands; Magnetic Resonance Spectroscopy; Male; Molecular Structure; Rats; Rats, Inbred Strains; Receptors, Purinergic; Structure-Activity Relationship; Vasodilation | 1990 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |